Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results.
Journal: Journal of inherited metabolic disease
Published: January 08, 2026
A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study.
Journal: Dermatology and therapy
Published: September 27, 2025
Long-Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency.
Journal: Journal of inherited metabolic disease
Published: May 06, 2025
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.
Journal: Therapeutic advances in neurological disorders
Published: June 14, 2024
Revisiting the meaning of cognitive impairment in older adults.
Journal: Journal of the American Geriatrics Society
Published: April 03, 2024
Depression, loneliness, and lower social activity as partial mediators of the association between visual impairment and cognitive decline.
Journal: International journal of geriatric psychiatry
Published: November 16, 2023
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Journal: Hematological oncology
Published: September 19, 2023
Application and validation of an algorithmic classification of early impairment in cognitive performance.
Journal: Aging & mental health
Published: June 24, 2023
Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
Journal: Orphanet journal of rare diseases
Published: June 07, 2023
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.
Journal: Haematologica
Published: March 22, 2023
Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results.
Journal: Orphanet journal of rare diseases
Published: March 15, 2023
Application and validation of an algorithmic classification of early impairment in cognitive performance.
Journal: medRxiv : the preprint server for health sciences
Published: February 17, 2023
Last Updated: 09/26/2026